Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia

Antimicrobial Agents and Chemotherapy
Shawn H MacVaneDavid P Nicolau

Abstract

Advanced-generation cephalosporins are frequently used for empirical coverage of ventilator-associated pneumonia (VAP) due to their activity against a broad spectrum of Gram-positive and Gram-negative aerobic bacteria, including Pseudomonas aeruginosa and Enterobacteriaceae. Providing optimal antibiotic exposure is essential to achieving successful response in patients with VAP. We evaluated exposures of two antipseudomonal cephalosporins, ceftazidime and cefepime, in patients with VAP due to Gram-negative bacilli to identify the pharmacodynamic parameter predictive of microbiological success. Population pharmacokinetic models were used to estimate individual free drug exposures. Pharmacodynamic indices were determined for each patient using the baseline Gram-negative bacilli with the highest drug MIC. Classification and regression tree analysis was utilized to partition exposure breakpoints, and multivariate logistic regression was conducted to identify predictors of microbiological success. A total of 73 patients (18 receiving ceftazidime therapy and 55 receiving cefepime therapy) were included. MICs ranged widely from 0.047 to 96 μg/ml. The microbiological success rate was 58.9%. Predictive breakpoints were identified for al...Continue Reading

References

Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
May 1, 1989·Diagnostic Microbiology and Infectious Disease·N ClynesH C Neu
Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Nov 1, 1993·The Journal of Antimicrobial Chemotherapy·G G Grassi, C Grassi
Jan 1, 1996·Antimicrobial Agents and Chemotherapy·D P NicolauR Quintiliani
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Jul 2, 1999·Antimicrobial Agents and Chemotherapy·C M GómezM G Palazzo
Jun 9, 2001·International Journal of Antimicrobial Agents·D P NicolauC H Nightingale
Apr 6, 2002·American Journal of Respiratory and Critical Care Medicine·Jean Chastre, Jean-Yves Fagon
May 13, 2003·Clinical Cornerstone·Douglas O Faigel
May 23, 2003·Antimicrobial Agents and Chemotherapy·Vincent H TamMichael J Rybak
Mar 20, 2004·Nature Reviews. Microbiology·George L Drusano
Aug 4, 2004·The Lancet Infectious Diseases
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Feb 20, 2007·Antimicrobial Agents and Chemotherapy·Chonghua LiDavid P Nicolau
Feb 25, 2009·Critical Care Medicine·Jason A Roberts, Jeffrey Lipman
Dec 30, 2009·Antimicrobial Agents and Chemotherapy·Jared L CrandonDavid P Nicolau
Jul 3, 2010·Critical Care : the Official Journal of the Critical Care Forum·Fabio Silvio TacconeFrédérique Jacobs
Jun 19, 2012·Expert Review of Anti-infective Therapy·Matteo BassettiPaolo Pelosi
Apr 20, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Helen W BoucherUNKNOWN Infectious Diseases Society of America
May 21, 2013·International Journal of Antimicrobial Agents·Niki I Paphitou

❮ Previous
Next ❯

Citations

Dec 19, 2015·Expert Review of Clinical Pharmacology·Marguerite L MonogueDavid P Nicolau
Jan 30, 2016·Critical Care : the Official Journal of the Critical Care Forum·Matteo BassettiRichard G Wunderink
Aug 21, 2015·Pharmacotherapy·Evan J ZasowskiMichael J Rybak
May 18, 2016·Expert Review of Respiratory Medicine·David P NicolauCharles-Edouard Luyt
Nov 1, 2016·Expert Review of Anti-infective Therapy·Matthew P Schreiber, Andrew F Shorr
Apr 4, 2018·Antimicrobial Agents and Chemotherapy·Wright W NicholsShampa Das
Dec 17, 2015·Antimicrobial Agents and Chemotherapy·Nathaniel J RhodesMarc H Scheetz
Jul 20, 2016·Antimicrobial Agents and Chemotherapy·Todd A RiccobeneTatiana Khariton
Oct 10, 2018·Current Opinion in Infectious Diseases·Aaron J HeffernanJason A Roberts
Jan 16, 2019·Antimicrobial Agents and Chemotherapy·Fabio ArenaGian Maria Rossolini
May 8, 2019·Antimicrobial Agents and Chemotherapy·Mordechai GrupperJoseph L Kuti
Dec 15, 2019·European Journal of Clinical Pharmacology·Shampa DasJianguo Li
Aug 1, 2018·Antimicrobial Agents and Chemotherapy·Wright W NicholsShampa Das
Feb 25, 2020·Interdisciplinary Perspectives on Infectious Diseases·Mohamed EladawyRasha Barwa
Jan 23, 2021·Pharmacotherapy·Andrew J FratoniJoseph L Kuti
Nov 6, 2018·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S K B SyH Derendorf
Jul 25, 2021·Paediatric Drugs·Anil R MaharajUNKNOWN Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee
Aug 13, 2021·The Journal of Antimicrobial Chemotherapy·Takayuki KatsubeToshihiro Wajima
Sep 18, 2021·Current Opinion in Infectious Diseases·Aaron J Heffernan, Jason A Roberts

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.